473453.pdf (858.36 kB)
0/0

Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue, PSA146-154

Download (858.36 kB)
journal contribution
posted on 27.06.2012 by Supriya Perambakam, Hui Xie, Seby Edassery, David J. Peace
Twenty eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate specific antigen, PSA146-154, between July 2002 to September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide specific delayed type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (p=0.02). Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months) per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.

Funding

The clinical trial was funded by grants from the National Cancer Institute (CA88062) and the Department of Army (DAMD17-98-1-8489). Funding for conducting correlative studies was supported by grants from the Illinois Department of Public Health (IDPH 4328301) and the Milheim Grant for Cancer Research, Denver, CO (award# 2007-24). Statistical analysis was made possible by a grant from the National Center for Research Resources (grant # UL1RR029879) awarded to the Center for Clinical and Translational Science, University of Illinois at Chicago.

History

Publisher Statement

Copyright © 2010 Supriya Perambakam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. doi 10.1155/2010/473453

Publisher

Hindawi Publishing Corporation

Language

en_US

issn

1740-2522

Issue date

01/01/2010

Exports